Arvinas is a pioneering biotechnology company committed to enhancing patient outcomes through the discovery and development of innovative therapies that target and degrade disease-causing proteins. Utilizing its proprietary PROTAC technology, Arvinas is at the forefront of creating solutions for patients facing debilitating diseases.